Loading article...
Loading article...
Stream/Area:
-
Subject:
-
Paper ID:
IJSREM41088
Volume:
9 |
1 |
Jan 2025
Pages:
Publication Frequency:
Monthly (12 issues per year)
License:International Journal of Scientific Research in Engineering and Management follows the Creative Commons Attribution 4.0 (CC BY 4.0) License, allowing free use and distribution with proper attribution.
Diclofenac sodium (DFS) is a widely prescribed nonsteroidal anti-inflammatory drug (NSAID) effective in managing pain and inflammation in patients with arthritis and musculoskeletal conditions. While DFS is known for its rapid analgesic effects and broad therapeutic indications, it also poses significant cardiovascular (CV) safety concerns. Research highlights that prolonged or high-dose use of diclofenac increases the risk of myocardial infarction, stroke, and thrombotic events. Despite clinical guidelines discouraging its use in patients with heart conditions, a large percentage of individuals continue its use after hospital discharge. This review explores the dual nature of diclofenac’s benefits for pain relief and its associated cardiovascular risks, discussing pharmacokinetics, therapeutic indications, adverse effects, and regulatory recommendations.
KEYWORDS
Publication Date
1/25/2025
Peer Review Type
Double-Blind Peer Review
Review Rounds: 2
Documents
Article Views
0
Total views since publication
PDF Downloads
3
Total downloads since publication
Geographic Reach
5
Digital Preservation: This article is permanently archived on Zenodo and complies with all data preservation standards across major indexing platforms.
Plagiarism Screening
This manuscript has been checked for plagiarism using TurnitinPlagiarismChecker software.
Conflict of Interest
The authors declare no conflict of interest related to this research work.
Funding Information
No funding information available for this research.
Related research in the same subject area
Loading similar articles...